Am I right in thinking another key difference between the MAST and OASIS trials is that patients enrolled on OASIS don’t need to have been through prior treatment lines?
If so, these patients may have a much more robust immune system for CF33(-CD19) to do its thing with.
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient, page-78
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $143.0K | 10.33M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 19360226 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 5956728 | 12 |
View Market Depth
| Last trade - 12.00pm 18/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |